TUESDAY, Jan. 3 (HealthDay News) -- The Prevnar 13 bacterial pneumonia vaccine has been approved for people aged 50 and older, the U.S. Food and Drug Administration said.
The vaccine targets pneumonia and other diseases caused by the bacterium Streptococcus pneumoniae. The shot, targeting 13 serotypes of the bacterium, has already been approved for children aged 6 weeks through 5 years to prevent invasive disease and certain ear infections, the agency said in a news release.
In clinical testing for the expanded use of the vaccine, people 50 and older were either given Prevnar 13 or another licensed pneumococcal vaccine, Pneumovax 23. The studies found Prevnar 13 induced levels of immune system antibodies that were either comparable or higher than those of Pneumovax 23, the FDA said.
Common side effects of Prevnar 13 included injection-site swelling, redness and pain, fatigue, headache, chills, muscle pain and joint pain.
An additional study in 85,000 people aged 65 or older is ongoing, the agency said.
Prevnar 13 is produced by Wyeth Pharmaceuticals, based in Collegeville, Penn.
The U.S. Centers for Disease Control and Prevention has more about pneumococcal disease.
Copyright © 2012 HealthDay. All rights reserved.